Using a special LED cap to treat a type of hair loss in women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to evaluate the effectiveness of the Revian Red All LED cap as a treatment for Central Centrifugal Cicatricial Alopecia (CCCA), a form of scarring hair loss primarily affecting middle-aged women of African descent. The study will enroll five participants who will use the cap daily for 10 minutes over a six-month period. The primary goal is to assess whether the treatment can halt hair loss progression, while secondary outcomes will focus on hair regrowth and symptom relief. Participants will undergo regular assessments, including standardized photos and questionnaires, to monitor their progress.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Women who are eighteen years of age or older with a biopsy-proven diagnosis of CCCA Stage II-III. They also must be on stable treatment without changes (on doxycycline, topical steroids, minoxidil and/or post 8 rounds of intralesional steroids) for at least 3 months.
* Subjects will be recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology.

Exclusion Criteria

* Subjects with other forms of hair loss that is not CCCA
* Prior treatment with light source for alopecia
* Males are excluded from this study since the prevalence of CCCA in males is so significantly low that it is difficult to find cases in a clinical setting

Where it's running

• Wake Forest School of Medicine - Dermatology Clinic
  Winston-Salem, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Amy McMichael, MD — Wake Forest University Health Sciences
• Study coordinator: Irma M Richardson, MHA
• Email: irichard@wakehealth.edu
• Phone: 336-716-2903

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Deucravacitinib for scarring hair loss (frontal fibrosing and central centrifugal alopecia)

  This trial will test whether taking deucravacitinib once daily for 48 weeks helps adults with frontal fibrosing alopecia or central centrifugal cicatricial alopecia.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07508488

• Topical delgocitinib 2% cream for Lichen Planopilaris and Central Centrifugal Cicatricial Alopecia

  This trial tests whether applying 2% delgocitinib cream twice daily is safe and changes scalp biomarkers in adults with Lichen Planopilaris or Central Centrifugal Cicatricial Alopecia over 48 weeks.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07487948

• Tirzepatide for Active Central Centrifugal Cicatricial Alopecia (CCCA)

  This pilot test will see if weekly tirzepatide can help adults with active CCCA regrow hair and reduce scarring.

  Recruiting at 2 sites Phase 2 Johns Hopkins University · Baltimore, Maryland and 1 other locations · NCT07734870

• Comparing treatments for hair loss in African-American women

  This study is testing two different treatment combinations for hair loss in African-American women with Central Centrifugal Cicatricial Alopecia to see which one works better.

  Recruiting Phase 4 Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT04207931

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.